BRAF gene

Overview

The BRAF gene (B-Raf proto-oncogene, serine/threonine kinase) encodes a cytoplasmic kinase that is a central node in the RAS–RAF–MEK–ERK mitogen-activated protein kinase (MAPK) signaling cascade. This pathway transduces extracellular growth signals into nuclear transcriptional programs governing cell proliferation, differentiation, and survival. BRAF phosphorylates and activates MEK1/2, which in turn phosphorylates ERK1/2, propagating mitogenic signals downstream to effectors such as p90RSK. Somatic mutations in BRAF—most notably the V600E substitution, wherein valine is replaced by glutamate at codon 600—constitutively activate kinase activity independent of upstream RAS input, driving uncontrolled tumor cell proliferation. Oncogenic BRAF alterations are found across a broad spectrum of human malignancies including melanoma, papillary thyroid carcinoma, glioma, and pancreatic cancer, establishing BRAF as one of the most clinically actionable oncogenes in modern precision oncology.

Beyond V600E, the BRAF locus harbors a spectrum of rarer activating mutations and structural rearrangements that vary in their functional consequences and therapeutic sensitivities. Cross-talk between BRAF and parallel survival pathways—particularly the PI3K/AKT axis involving Akt1—means that oncogenic BRAF signaling is rarely isolated, and co-occurring alterations in genes such as KRAS can modulate both tumor behavior and responsiveness to targeted inhibition. The clinical significance of BRAF is underscored by the approval of multiple small-molecule BRAF inhibitors and their combinations with MEK inhibitors, which have transformed outcomes in BRAF V600E-driven Cancers.

Recent Publications Summary

Recent publications on BRAF focused on both therapeutic targeting and clinical management across several BRAF-altered Cancers. A joint SNO/EANO consensus review summarized current evidence for diagnosing and treating BRAF-altered glioma in adults and children, emphasizing molecular testing, selection and monitoring of targeted therapies, toxicity management, resistance, and areas where evidence remains limited 42261252Jun. In EGFR-mutated advanced NSCLC with acquired BRAF alterations after progression on first-line osimertinib, the ORCHARD platform study reported final results for osimertinib plus selumetinib, a MEK inhibitor, in this biomarker-matched setting 42202477May.

Several studies examined BRAF-directed therapy in melanoma and other BRAF-mutant tumors. A nationwide Italian study of rare BRAF mutations in melanoma found that these variants were uncommon and that outcomes with BRAF/MEK inhibitors were broadly comparable to V600E/K-mutant disease, although response rates were numerically lower; immunotherapy outcomes were not affected by BRAF status 42003243Apr. In parallel, medicinal chemistry work identified a pyrimido[4,5-d]pyrimidine compound with selective binding to BRAF V600E, but only modest antiproliferative activity in cancer cells despite strong biochemical affinity 42208521May. Another study linked FGD1 to secondary resistance to BRAF inhibition in melanoma, showing that FGD1 knockdown reduced proliferation, induced resistance to BRAF inhibition, and increased sensitivity to p21-activated kinase inhibition, while prolonged BRAF inhibitor exposure was associated with reduced FGD1 levels 41802101Mar.

Other reports extended BRAF biology to hematologic and histiocytic malignancies and to colorectal cancer. A case report described secondary BRAF-mutated histiocytic/dendritic cell sarcoma arising from follicular lymphoma, with a sustained 18-month response to BRAF/MEK inhibition before later evolution to high-grade B-cell lymphoma harboring MYC and BCL2 rearrangements 42264920Jun. In drug-resistant colorectal cancer, a molecular glue degrader was reported to target mutant BRAF by disrupting mRNA splicing 42447212Jul. Additional work in BRAF-mutant colon cancer organoids showed that non-genetic factors such as seeding density, organoid size, and morphology influenced growth kinetics, trametinib sensitivity, and Wnt dynamics, underscoring the importance of experimental context in functional drug-response studies 41833556Mar.

safety and disease characterization studies also contributed to the recent literature. A WHO pharmacovigilance analysis of BRAF and MEK inhibitors found that cutaneous adverse drug reactions were common in real-world reporting, with rash the predominant event across agents and a notable disproportionality signal for dermatitis acneiform with selumetinib 42177750May. In BRAF-mutant papillary thyroid cancer, one study examined whether isthmus topography was associated with distinct molecular characteristics, while another investigated the spectrum of rare BRAF mutations in melanoma and their structural and functional consequences, including variable destabilization toward constitutive activation for variants affecting codons 599–601 42055630Apr42003243Apr.

What Changes, What Holds

1. BRAF-altered disease now has a broader management framework, but the core signaling model stands
REINFORCES Adult and pediatric glioma guidance, plus the osimertinib-plus-selumetinib report in acquired BRAF-altered NSCLC, extend the clinical reach of BRAF-directed thinking without changing the baseline biology of BRAF as a MAPK-pathway kinase. The main implication is practical: testing, toxicity monitoring, resistance assessment, and biomarker matching are becoming more explicit parts of care in BRAF-altered Cancers 42261252Jun42202477May.

2. Rare BRAF variants can be treated as actionable, but their biology is less uniform than V600E
REINFORCES The melanoma data support the baseline view that non-V600 BRAF alterations belong within the actionable oncogene framework, while also showing that not all variants behave identically in response depth. The medicinal chemistry and FGD1 findings add therapeutic and resistance nuance, but they do not displace the established role of BRAF inhibition; instead they sharpen expectations about selectivity, modest cellular potency, and adaptive resistance mechanisms 42003243Apr42208521May41802101Mar.

3. BRAF alterations are appearing in additional resistant and histiocytic settings, but these are extensions of known oncogenic use rather than a new biology
NEW DIRECTION The histiocytic/dendritic sarcoma case and the colorectal degrader study broaden the disease contexts in which mutant BRAF can be targeted, and the organoid work warns that experimental context can strongly shape apparent trametinib sensitivity. None of this overturns the baseline account of BRAF as an oncogenic kinase; it instead adds new therapeutic and methodological territory beyond the Cancers already emphasized there 42264920Jun42447212Jul41833556Mar.

4. Real-world toxicity and variant-specific pathology now need to be part of BRAF management
REINFORCES Pharmacovigilance data strengthen the need for routine adverse-event surveillance during BRAF/MEK inhibition, especially for cutaneous reactions, and the papillary thyroid cancer and melanoma pathology studies refine how rare variants and tumor location may be interpreted. These findings do not challenge the baseline therapeutic framework; they make it more clinically complete by emphasizing safety, heterogeneity, and structural-functional diversity among rare BRAF mutations 42177750May42055630Apr42003243Apr.

Overview update candidates: clinical guidance for BRAF-altered glioma and biomarker-matched NSCLC combinations; recognition that rare BRAF variants can have broadly comparable but not identical inhibitor sensitivity; real-world cutaneous toxicity surveillance for BRAF/MEK inhibitors.